Wrapping up Q3 earnings, we look at the numbers and key takeaways for the leisure facilities stocks, including European Wax Center (NASDAQ:EWCZ) and its peers. Leisure facilities companies often sell ...

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is ...

How often should you wax your car? That depends on a few factors, including the type of wax you use. Conventional paste wax is harder to apply due to its thick consistency and typically offers three ...

Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company’s Moderate operating performance ...

Shares of Johnson & Johnson were rising into record territory in early trading Tuesday, after the medicines and medical-technology giant beat quarterly earnings expectations and raised its outlook, ...

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter ...

The man accused of pointing a gun at Cincinnati police in Fountain Square during Taste of Cincinnati weekend was resentenced Thursday.Jabari Johnson was resentenced to six months in prison after lying ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Johnson & Johnson ( (JNJ)) has provided ...

Marv restores a King Manufacturing 500 Shot BB Gun from his childhood, made between 1926 and 1935. The restoration process includes sandblasting and painting the body, along with plans to replace the ...

SIOUX FALLS, S.D. (KELO/AP) — A bill in Washington with bipartisan backing would prevent members of Congress from trading of individual stocks. Among the supporters is South Dakota’s only member of ...

Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech ...